{"id":66756,"date":"2026-05-29T22:09:31","date_gmt":"2026-05-29T14:09:31","guid":{"rendered":"https:\/\/flcube.com\/?p=66756"},"modified":"2026-05-29T22:09:32","modified_gmt":"2026-05-29T14:09:32","slug":"northland-biotechs-engensis-gene-therapy-receives-nmpa-approval-for-severe-lower-limb-ischemia-ulcers","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66756","title":{"rendered":"Northland Biotech&#8217;s Engensis Gene Therapy Receives NMPA Approval for Severe Lower Limb Ischemia Ulcers"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Beijing Northland Biotechnology Co., Ltd.<\/strong> announced that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has granted <strong>marketing approval<\/strong> for <strong>engensis<\/strong>, a <strong>naked plasmid gene therapy<\/strong>, for the treatment of <strong>limb ulcers caused by severe lower limb ischemia<\/strong> in patients unsuitable for revascularization surgery or with poor surgical outcomes. The therapy addresses critical unmet needs in <strong>atherosclerosis obliterans, thromboangiitis obliterans, and diabetic lower limb ischemia<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone-amp-clinical-indication\" class=\"wp-block-heading\">Regulatory Milestone &amp; Clinical Indication<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Regulatory Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Marketing authorization<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Limb ulcers from severe lower limb ischemia<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Unsuitable for revascularization surgery or poor surgical outcomes<\/td><\/tr><tr><td><strong>Etiologies Covered:<\/strong><\/td><td><\/td><\/tr><tr><td>\u2022 Atherosclerosis obliterans<\/td><td>\u2713<\/td><\/tr><tr><td>\u2022 Thromboangiitis obliterans<\/td><td>\u2713<\/td><\/tr><tr><td>\u2022 Diabetic lower limb ischemia<\/td><td>\u2713<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Therapy Class:<\/strong> Naked plasmid gene therapy<\/li>\n\n\n\n<li><strong>Vector System:<\/strong> pCK vector with efficient target gene expression<\/li>\n\n\n\n<li><strong>Active Component:<\/strong> Hybrid hepatocyte growth factor gene (HGF-X7)<\/li>\n\n\n\n<li><strong>Administration:<\/strong> Intramuscular injection<\/li>\n\n\n\n<li><strong>Cellular Target:<\/strong> Striated muscle cells<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-molecular-mechanism\" class=\"wp-block-heading\">Molecular Mechanism<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Gene Expression:<\/strong> Transfected muscle cells express and secrete two HGF isoforms (HGF723 and HGF728)<\/li>\n\n\n\n<li><strong>Receptor Binding:<\/strong> HGF proteins bind to c-Met tyrosine kinase receptor on vascular endothelial cells<\/li>\n\n\n\n<li><strong>Biological Effects:<\/strong><\/li>\n\n\n\n<li>Stimulates endothelial cell proliferation<\/li>\n\n\n\n<li>Promotes migration of endothelial and smooth muscle cells<\/li>\n\n\n\n<li>Induces local angiogenesis<\/li>\n\n\n\n<li>Establishes collateral circulation<\/li>\n\n\n\n<li>Improves lower limb blood perfusion<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-pivotal-phase-iii-clinical-evidence\" class=\"wp-block-heading\">Pivotal Phase III Clinical Evidence<\/h2>\n\n\n\n<h3 id=\"h-hope-clti-2-study-results\" class=\"wp-block-heading\">HOPE CLTI-2 Study Results<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result<\/th><th>Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Complete ulcer healing rate<\/td><td><strong>Significantly higher vs. placebo<\/strong><\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Adverse events<\/td><td><strong>Similar to placebo<\/strong><\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Severe lower limb ischemia with limb ulcers<\/td><td>High unmet medical need<\/td><\/tr><tr><td><strong>Treatment Paradigm<\/strong><\/td><td>Non-surgical option for revascularization-ineligible patients<\/td><td>Addresses critical gap in care<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-market-opportunity-amp-therapeutic-context\" class=\"wp-block-heading\">Market Opportunity &amp; Therapeutic Context<\/h2>\n\n\n\n<h3 id=\"h-critical-limb-ischemia-landscape-in-china\" class=\"wp-block-heading\">Critical Limb Ischemia Landscape in China<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patient Burden:<\/strong> Estimated 2-3 million patients with severe lower limb ischemia<\/li>\n\n\n\n<li><strong>Surgical Limitations:<\/strong> 30-40% of patients unsuitable for revascularization procedures<\/li>\n\n\n\n<li><strong>Current Treatment Gaps:<\/strong> Limited effective non-surgical options for ulcer healing<\/li>\n\n\n\n<li><strong>Amputation Risk:<\/strong> High rates of major amputation without effective intervention<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-competitive-therapeutic-approaches\" class=\"wp-block-heading\">Competitive Therapeutic Approaches<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Approach<\/th><th>Current Options<\/th><th>Limitations<\/th><th>Engensis Advantage<\/th><\/tr><\/thead><tbody><tr><td><strong>Revascularization Surgery<\/strong><\/td><td>Bypass, endovascular procedures<\/td><td>30-40% ineligible, high complication rates<\/td><td><strong>Non-surgical alternative<\/strong><\/td><\/tr><tr><td><strong>Wound Care<\/strong><\/td><td>Standard dressings, debridement<\/td><td>Limited efficacy in ischemic ulcers<\/td><td><strong>Addresses underlying ischemia<\/strong><\/td><\/tr><tr><td><strong>Growth Factor Therapies<\/strong><\/td><td>Limited availability<\/td><td>Short half-life, repeated administration<\/td><td><strong>Sustained local HGF expression<\/strong><\/td><\/tr><tr><td><strong>Cell Therapies<\/strong><\/td><td>Experimental approaches<\/td><td>Complex manufacturing, regulatory hurdles<\/td><td><strong>Simple plasmid-based gene therapy<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<h3 id=\"h-for-northland-biotechnology\" class=\"wp-block-heading\">For Northland Biotechnology<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-in-Class Status:<\/strong> First approved gene therapy for lower limb ischemia in China<\/li>\n\n\n\n<li><strong>Commercial Pioneer:<\/strong> Establishes leadership in cardiovascular gene therapy market<\/li>\n\n\n\n<li><strong>Manufacturing Advantage:<\/strong> Plasmid-based approach enables scalable, cost-effective production<\/li>\n\n\n\n<li><strong>Global Potential:<\/strong> Positive Phase III data supports international regulatory filings<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-china-cardiovascular-gene-therapy-market\" class=\"wp-block-heading\">China Cardiovascular Gene Therapy Market<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regulatory Innovation:<\/strong> NMPA approval reflects evolving framework for advanced therapies<\/li>\n\n\n\n<li><strong>Healthcare Economics:<\/strong> Potential to reduce amputation costs and improve quality of life<\/li>\n\n\n\n<li><strong>Reimbursement Pathway:<\/strong> High clinical value may support premium pricing and NRDL inclusion<\/li>\n\n\n\n<li><strong>Physician Education:<\/strong> Need for training on gene therapy administration and patient selection<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-implementation-strategy-amp-commercial-outlook\" class=\"wp-block-heading\">Implementation Strategy &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Launch Timeline:<\/strong> Expected Q3-Q4 2026<\/li>\n\n\n\n<li><strong>Target Facilities:<\/strong> Vascular surgery centers, wound care clinics, diabetes foot centers<\/li>\n\n\n\n<li><strong>Distribution Model:<\/strong> Direct sales force with specialized training requirements<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Estimated \u00a5400-600 million annual peak sales in Chinese CLI market<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding market launch, commercial performance, and regulatory compliance for engensis. Actual results may differ due to risks including market adoption challenges, healthcare policy changes, competitive dynamics, and evolving standards of care for critical limb ischemia.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Beijing Northland Biotechnology Co., Ltd. announced that China&#8217;s National Medical Products Administration (NMPA) has granted&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[4764,15],"class_list":["post-66756","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-northland-biotechnology","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Northland Biotech&#039;s Engensis Gene Therapy Receives NMPA Approval for Severe Lower Limb Ischemia Ulcers - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Beijing Northland Biotechnology Co., Ltd. announced that China&#039;s National Medical Products Administration (NMPA) has granted marketing approval for engensis, a naked plasmid gene therapy, for the treatment of limb ulcers caused by severe lower limb ischemia in patients unsuitable for revascularization surgery or with poor surgical outcomes. The therapy addresses critical unmet needs in atherosclerosis obliterans, thromboangiitis obliterans, and diabetic lower limb ischemia.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66756\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Northland Biotech&#039;s Engensis Gene Therapy Receives NMPA Approval for Severe Lower Limb Ischemia Ulcers\" \/>\n<meta property=\"og:description\" content=\"Beijing Northland Biotechnology Co., Ltd. announced that China&#039;s National Medical Products Administration (NMPA) has granted marketing approval for engensis, a naked plasmid gene therapy, for the treatment of limb ulcers caused by severe lower limb ischemia in patients unsuitable for revascularization surgery or with poor surgical outcomes. The therapy addresses critical unmet needs in atherosclerosis obliterans, thromboangiitis obliterans, and diabetic lower limb ischemia.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66756\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-29T14:09:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-29T14:09:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66756#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66756\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Northland Biotech&#8217;s Engensis Gene Therapy Receives NMPA Approval for Severe Lower Limb Ischemia Ulcers\",\"datePublished\":\"2026-05-29T14:09:31+00:00\",\"dateModified\":\"2026-05-29T14:09:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66756\"},\"wordCount\":562,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Northland Biotechnology\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66756#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66756\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66756\",\"name\":\"Northland Biotech's Engensis Gene Therapy Receives NMPA Approval for Severe Lower Limb Ischemia Ulcers - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-29T14:09:31+00:00\",\"dateModified\":\"2026-05-29T14:09:32+00:00\",\"description\":\"Beijing Northland Biotechnology Co., Ltd. announced that China's National Medical Products Administration (NMPA) has granted marketing approval for engensis, a naked plasmid gene therapy, for the treatment of limb ulcers caused by severe lower limb ischemia in patients unsuitable for revascularization surgery or with poor surgical outcomes. The therapy addresses critical unmet needs in atherosclerosis obliterans, thromboangiitis obliterans, and diabetic lower limb ischemia.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66756#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66756\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66756#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Northland Biotech&#8217;s Engensis Gene Therapy Receives NMPA Approval for Severe Lower Limb Ischemia Ulcers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Northland Biotech's Engensis Gene Therapy Receives NMPA Approval for Severe Lower Limb Ischemia Ulcers - Insight, China&#039;s Pharmaceutical Industry","description":"Beijing Northland Biotechnology Co., Ltd. announced that China's National Medical Products Administration (NMPA) has granted marketing approval for engensis, a naked plasmid gene therapy, for the treatment of limb ulcers caused by severe lower limb ischemia in patients unsuitable for revascularization surgery or with poor surgical outcomes. The therapy addresses critical unmet needs in atherosclerosis obliterans, thromboangiitis obliterans, and diabetic lower limb ischemia.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66756","og_locale":"en_US","og_type":"article","og_title":"Northland Biotech's Engensis Gene Therapy Receives NMPA Approval for Severe Lower Limb Ischemia Ulcers","og_description":"Beijing Northland Biotechnology Co., Ltd. announced that China's National Medical Products Administration (NMPA) has granted marketing approval for engensis, a naked plasmid gene therapy, for the treatment of limb ulcers caused by severe lower limb ischemia in patients unsuitable for revascularization surgery or with poor surgical outcomes. The therapy addresses critical unmet needs in atherosclerosis obliterans, thromboangiitis obliterans, and diabetic lower limb ischemia.","og_url":"https:\/\/flcube.com\/?p=66756","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-29T14:09:31+00:00","article_modified_time":"2026-05-29T14:09:32+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66756#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66756"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Northland Biotech&#8217;s Engensis Gene Therapy Receives NMPA Approval for Severe Lower Limb Ischemia Ulcers","datePublished":"2026-05-29T14:09:31+00:00","dateModified":"2026-05-29T14:09:32+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66756"},"wordCount":562,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Northland Biotechnology","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66756#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66756","url":"https:\/\/flcube.com\/?p=66756","name":"Northland Biotech's Engensis Gene Therapy Receives NMPA Approval for Severe Lower Limb Ischemia Ulcers - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-29T14:09:31+00:00","dateModified":"2026-05-29T14:09:32+00:00","description":"Beijing Northland Biotechnology Co., Ltd. announced that China's National Medical Products Administration (NMPA) has granted marketing approval for engensis, a naked plasmid gene therapy, for the treatment of limb ulcers caused by severe lower limb ischemia in patients unsuitable for revascularization surgery or with poor surgical outcomes. The therapy addresses critical unmet needs in atherosclerosis obliterans, thromboangiitis obliterans, and diabetic lower limb ischemia.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66756#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66756"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66756#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Northland Biotech&#8217;s Engensis Gene Therapy Receives NMPA Approval for Severe Lower Limb Ischemia Ulcers"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66756","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66756"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66756\/revisions"}],"predecessor-version":[{"id":66759,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66756\/revisions\/66759"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66756"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66756"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66756"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}